Topics

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic, Date of authorisation: 27/09/2017, Revision: 5, Status: Authorised

06:26 EDT 3 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic, Date of authorisation: 27/09/2017, Revision: 5, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic, Date of authorisation: 27/09/2017, Revision: 5, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic, Date of authorisation: 27/09/2017, Revision: 5, Status: Authorised"

Quick Search

Relevant Topic

Dermatitis
Dermatitis means an inflammation of the skin. Contact dermatitis is a term used when this inflammation is caused by contact with something in the environment. The changes of dermatitis seen in the skin take the form of eczema; hence it may sometimes be r...